Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
Early Treatment of Amyotrophic Lateral Sclerosis With Nutrition and Non-Invasive Positive Pressure Ventilation
The purposes of the study are to determine the energy balance and evaluate the nutritional status of patients with ALS, and to investigate the use of NIPPV as respiratory support to treat patients with ALS.
Studies to date indicate that percutaneous endoscopic gastrostomy (PEG)—insertion of a
feeding tube in the stomach—and non-invasive positive pressure ventilation
(NIPPV)—mechanically assisted or generated breaths delivered through a tightly fitting nasal
or facial mask—improve survival in amyotrophic lateral sclerosis (ALS), even when introduced
late in the disease.
Dr. Kasarskis and his research team believe early intervention with these treatments may
improve patients outcome even further. However, many issues regarding the early use of these
treatments prevent the design of a phase III clinical trial to test this hypothesis. Common
to both NIPPV and nutrition is a lack of a reliable indicator of early respiratory or
nutritional insufficiency. With respect to nutrition, reliable and cost effective methods are
needed to determine a patient's energy (i.e. caloric) requirements at different stages of the
illness to establish a basis for recommending PEG on the adequacy of energy intake. For
NIPPV, factors that influence acceptance and tolerability of this therapy, and measurements
of early respiratory dysfunction need to be identified.
The purposes of this trial are to develop and validate strategies to improve tolerability of
NIPPV, identify factors that influence acceptance of NIPPV, and evaluate measures of early
respiratory failure, other than percentage of forced vital capacity (FVC). Researchers will
also develop and validate methods to determine energy balance in and evaluate the nutritional
status of patients with ALS that will be applicable to a multi-center phase III study of
nutrition and NIPPV.
The study will be conducted at 11 other sites across the country. Some study sites will focus
on the nutritional aspects of the trial while the other sites will focus on NIPPV treatment.
A total of 220 patients will be studied over 2 years.
Enrollment will end on June 30, 2007. The last patient was followed clinically until June 30,
2008. The study remained open for sample analysis, data analysis, and assessment of vital
status until the completion of funding on November 30, 2009.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |